Next generation bioanalytical solutions
- Fill out request form
- Receive, review, and sign NDA
- Review term sheet for license
- Discuss details of license, finalize, sign and pay fees
- Obtain cells under license
Neukopanel® Cell Request Form
for Proprietary Neukoplast® NK-92 Cells
Please complete form to initiate licensing process
Taking you beyond the Brink of binding™
with our Killer Assays™.
THE NK-92® ASSAY COMPANY
Brink Biologics, Inc. (BBI) is a ImmunityBio, Inc. (NASDAQ: IBRX) affiliated biotechnology solutions company located in the prestigious Torrey Pines biotechnology science park in San Diego, CA.
KILLER CELLS - KILLER ASSAYS™
Natural Killer cell lines originating from a singular source, established in stable cultures under GLP & cGMP conditions and further modified into multiple panels of lines suitable for a range of laboratory testing applications.
Proprietary NEUKOPANEL® CELL LINES
A standardized panel of CD16 expressing NK-92® cell lines, provides for the first time the means to establish a consistent, robust and reliable assay for assessment of ADCC activity.
ADCC ASSAYS – ROUTINE HASSLE
Brink Biologics, Inc. holds the exclusive non-clinical rights to the NK-92®️ cell line and its CD16 expressing derivatives, all of which are uniquely and ideally suited for antibody-dependent cell-mediated cytotoxicity (ADCC) assays.
OUR SIMPLE SOLUTION
The exclusive global provider of NK-92® cell line testing services, products, and sublicenses within the life sciences and device industry.
Highly published cell lines – over 200 publications.
Schnueriger, A., et al. (2011). “Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.” Mol Immunol 48(12-13): 1512-1517.
Binyamin, L., et al. (2008). “Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.” J Immunol 180(9): 6392-6401.
NK-92® cells are the only continuously growing human NK cell adapted to mass production
Brink Biologics created the NK-92® master cell bank (MCB).
Five Advantages of Neukopanel® Cell Lines:
For the first time the means to establish a consistent, robust and reliable assay for assessment of true ADCC function.
Cost & Time Savings
Ease of Use
Eliminates Phenotypic Variability
- Cost and time savings over common practice using donor-sourced (PBMC) NK cell isolation, expansion and maintenance in short term cultures
- Eliminates phenotypic variability of donor-sourced NK cells as Neukopanel cell lines offer clonal consistency, purity and reliability as an assay reagent
- Ease of use over donor-sourced NK cells and capable of long-term continuous cultures
- Ability to generate a readout spectrum with the use of our homozygous high and low affinity CD16 expressing lines alongside our negative control line for assay robustness
- True cytotoxicity rather than cell-binding readouts
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
SAN DIEGO, Calif., September 10, 2020 – Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of...
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO--May 1, 2019-- Brink Biologics, Inc., a NantKwest,...
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019CULVER CITY, CA - April 1, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced...
3530 John Hopkins Court
San Diego, CA 92121
8am to 5pm M-F
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.